177 related articles for article (PubMed ID: 2659565)
1. Effect of Bacteroides fragilis on mortality induced by Escherichia coli in an experimental infection treated with cefotaxime, aztreonam or gentamicin.
Soriano F; Ponte C; Santamaría M; Castilla C
J Antimicrob Chemother; 1989 Mar; 23(3):383-8. PubMed ID: 2659565
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
Beale AS; Gisby J
J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
[TBL] [Abstract][Full Text] [Related]
3. beta-Lactamase produced by a highly beta-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections.
Ajiki Y; Koga T; Ohya S; Takenouchi T; Yasuda H; Watanabe K; Ueno K
J Antimicrob Chemother; 1991 Oct; 28(4):537-46. PubMed ID: 1761449
[TBL] [Abstract][Full Text] [Related]
4. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
Brook I
J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftizoxime and comparative compounds against Bacteroides fragilis in a mouse model of anaerobic infection.
Grappel SF; Phillips L; Actor P
J Antibiot (Tokyo); 1984 Apr; 37(4):384-8. PubMed ID: 6327593
[TBL] [Abstract][Full Text] [Related]
6. Aztreonam vs. gentamicin in experimental peritonitis and intra-abdominal abscess formation.
Sawyer RG; Adams RB; Pruett TL
Am Surg; 1994 Nov; 60(11):849-53. PubMed ID: 7978680
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.
Beale AS; Gisby J
Infection; 1991; 19(2):101-5. PubMed ID: 2050417
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Brook I
Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
10. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
11. In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.
Brook I; Gillmore JD
J Antimicrob Chemother; 1993 Mar; 31(3):393-401. PubMed ID: 8486573
[TBL] [Abstract][Full Text] [Related]
12. In vivo significance of the inoculum effect of antibiotics on Escherichia coli.
Soriano F; Santamaría M; Ponte C; Castilla C; Fernández-Roblas R
Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):410-2. PubMed ID: 3137046
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
14. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
Brook I; Ledney GD
J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis.
Montravers P; Andremont A; Massias L; Carbon C
J Infect Dis; 1994 Apr; 169(4):821-30. PubMed ID: 8133097
[TBL] [Abstract][Full Text] [Related]
16. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.
Gisby J; Beale AS
Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924
[TBL] [Abstract][Full Text] [Related]
19. The role of Candida albicans in the pathogenesis of experimental fungal/bacterial peritonitis and abscess formation.
Sawyer RG; Adams RB; Rosenlof LK; May AK; Pruett TL
Am Surg; 1995 Aug; 61(8):726-31. PubMed ID: 7618816
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of temafloxacin in a rat model of intra-abdominal abscess.
Thadepalli H; Hajji M; Perumal VK; Chuah SK; Gollapudi S
J Antimicrob Chemother; 1992 Jun; 29(6):687-92. PubMed ID: 1324241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
